XJPX6039
Market cap40mUSD
Jan 17, Last price
2,308.00JPY
1D
-0.56%
1Q
17.10%
Jan 2017
47.95%
IPO
13.14%
Name
Japan Animal Referral Medical Center Co Ltd
Chart & Performance
P/E
18.72
P/S
1.48
EPS
123.29
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
6.31%
Revenues
4.27b
+10.26%
Net income
337m
-11.41%
CFO
900m
+10.96%
Dividend
Mar 28, 20250 JPY/sh
Profile
Japan Animal Referral Medical Center Co., Ltd. owns and operates medical centers for animals in Japan. Its veterinary hospital provides advanced medical care service for dogs and cats. The company's medical center comprises cardiology, respiratory, urology, gastroenterology, oncology, neurology, orthopedics, ophthalmology, radiology and imaging, and anesthesiology departments. It also provides professional training services, such as clinical training and treatment; and conducts research and development projects, including genetic testing, immunotherapy, and regenerative medicine. Japan Animal Referral Medical Center Co., Ltd. was incorporated in 2005 and is headquartered in Kawasaki, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | |
| Income | |||||
Revenues | 4,270,195 10.26% | 3,872,994 30.01% | 2,979,011 4.61% | ||
Cost of revenue | 3,681,547 | 3,196,053 | 2,448,597 | ||
Unusual Expense (Income) | |||||
NOPBT | 588,648 | 676,941 | 530,414 | ||
NOPBT Margin | 13.79% | 17.48% | 17.81% | ||
Operating Taxes | 154,088 | 153,268 | 136,644 | ||
Tax Rate | 26.18% | 22.64% | 25.76% | ||
NOPAT | 434,560 | 523,673 | 393,770 | ||
Net income | 337,217 -11.41% | 380,664 32.66% | 286,939 0.61% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | (266,592) | 775,799 | (113,204) | ||
BB yield | 4.97% | -17.14% | 2.58% | ||
| Debt | |||||
Debt current | 626,493 | 582,517 | 546,376 | ||
Long-term debt | 3,230,051 | 3,393,164 | 3,375,581 | ||
Deferred revenue | 75,044 | 67,601 | |||
Other long-term liabilities | 90,111 | 16,792 | 23,084 | ||
Net debt | 2,279,905 | 1,868,642 | 2,695,362 | ||
| Cash flow | |||||
Cash from operating activities | 899,782 | 810,922 | 557,574 | ||
CAPEX | (1,055,193) | (741,938) | (601,937) | ||
Cash from investing activities | (985,860) | (784,065) | (1,425,741) | ||
Cash from financing activities | (392,322) | 820,586 | 722,091 | ||
FCF | (383,975) | (48,282) | (168,659) | ||
| Balance | |||||
Cash | 1,337,639 | 1,916,039 | 1,068,595 | ||
Long term investments | 239,000 | 191,000 | 158,000 | ||
Excess cash | 1,363,129 | 1,913,389 | 1,077,644 | ||
Stockholders' equity | 3,509,399 | 3,166,557 | 2,381,292 | ||
Invested Capital | 6,394,952 | 5,711,093 | 5,356,359 | ||
ROIC | 7.18% | 9.46% | 8.23% | ||
ROCE | 7.49% | 8.74% | 8.04% | ||
| EV | |||||
Common stock shares outstanding | 2,781 | 2,485 | 2,432 | ||
Price | 1,930.00 5.93% | 1,822.00 0.83% | 1,807.00 -13.13% | ||
Market cap | 5,366,792 18.55% | 4,527,218 3.03% | 4,394,057 -13.35% | ||
EV | 7,646,697 | 6,395,860 | 7,089,419 | ||
EBITDA | 1,053,118 | 1,088,782 | 771,414 | ||
EV/EBITDA | 7.26 | 5.87 | 9.19 | ||
Interest | 22,093 | 17,592 | 12,385 | ||
Interest/NOPBT | 3.75% | 2.60% | 2.33% | ||